Clinical and preclinical evidence highlight the efficacy of intranasal insulin (INI) in treating Alzheimer's disease (AD) and delirium, with studies showing significant improvements in cognitive scores and reduced hospital stays (7.9 vs. 12.9 days; <i>p</i> = 0.014). Here, INS is linked to early-onset autosomal dominant Alzheimer disease.